Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y
Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311
PMC: 11889221.
DOI: 10.1038/s41392-025-02124-y.
Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y
Nat Commun. 2025; 16(1):2175.
PMID: 40038297
PMC: 11880398.
DOI: 10.1038/s41467-025-57465-7.
Wan M, Pan S, Shan B, Diao H, Jin H, Wang Z
Mol Cancer. 2025; 24(1):61.
PMID: 40025508
PMC: 11874147.
DOI: 10.1186/s12943-025-02258-1.
Chen Y, Xue C
Front Cell Dev Biol. 2025; 12:1517181.
PMID: 40012992
PMC: 11860889.
DOI: 10.3389/fcell.2024.1517181.
Zhou B, Chen M, Hao Z, Li L, Zhang Y, Fang B
J Nanobiotechnology. 2025; 23(1):137.
PMID: 39994712
PMC: 11849371.
DOI: 10.1186/s12951-025-03186-4.
Linking macrophage metabolism to function in the tumor microenvironment.
Jin R, Neufeld L, McGaha T
Nat Cancer. 2025; 6(2):239-252.
PMID: 39962208
DOI: 10.1038/s43018-025-00909-2.
Nanoparticles Modulating the Immune Microenvironment in Breast Cancer Treatment.
Guo L, Wu J, Lu W, Li J, Wang Y, Yang H
Int J Nanomedicine. 2025; 20:1367-1382.
PMID: 39917056
PMC: 11799854.
DOI: 10.2147/IJN.S492713.
Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions.
Yan M, Cui Y, Xiang Q
Theranostics. 2025; 15(5):1715-1740.
PMID: 39897543
PMC: 11780521.
DOI: 10.7150/thno.106597.
Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy.
Yan W, Wang S, Zhu L, Yu X, Li J
Apoptosis. 2025; .
PMID: 39870938
DOI: 10.1007/s10495-024-02032-6.
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.
Feng Q, Shan X, Yau V, Cai Z, Xie S
Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861125
PMC: 11769033.
DOI: 10.3390/ph18010062.
Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics.
Chen S, Fei Y, Cai X, Wang C, Tong S, Zhang Z
Front Endocrinol (Lausanne). 2025; 15():1528248.
PMID: 39850483
PMC: 11754047.
DOI: 10.3389/fendo.2024.1528248.
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J
Front Immunol. 2024; 15:1513421.
PMID: 39735530
PMC: 11671371.
DOI: 10.3389/fimmu.2024.1513421.
Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors.
Cho M, Chang H, Kim J
Cancer Immunol Immunother. 2024; 74(1):28.
PMID: 39708127
PMC: 11663206.
DOI: 10.1007/s00262-024-03839-7.
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K
Cell Rep Med. 2024; 5(11):101825.
PMID: 39566464
PMC: 11604547.
DOI: 10.1016/j.xcrm.2024.101825.
Integrated analysis reveals prognostic correlation and immune characteristics of a tumor-associated macrophage-based risk signature in triple-negative breast cancer.
Miao S, Bian C, Fang J, Wang S, You H, Zhou Y
Transl Cancer Res. 2024; 13(10):5214-5232.
PMID: 39525038
PMC: 11543029.
DOI: 10.21037/tcr-24-1037.
Targeting of TAMs: can we be more clever than cancer cells?.
Kzhyshkowska J, Shen J, Larionova I
Cell Mol Immunol. 2024; 21(12):1376-1409.
PMID: 39516356
PMC: 11607358.
DOI: 10.1038/s41423-024-01232-z.
AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization.
Liu Z, Hu S, Zhao X, Xu W, Ju F, Gu M
J Immunother Cancer. 2024; 12(10).
PMID: 39448199
PMC: 11499773.
DOI: 10.1136/jitc-2024-009877.
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment.
Baharom F, Hermans D, Delamarre L, Seder R
Nat Rev Immunol. 2024; 25(3):195-211.
PMID: 39433884
DOI: 10.1038/s41577-024-01091-9.
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.
Yang Y, Li H, Yang W, Shi Y
Front Immunol. 2024; 15:1441667.
PMID: 39430759
PMC: 11487198.
DOI: 10.3389/fimmu.2024.1441667.
Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus.
Tang S, Lyles K, Wang Y, Fan D, Luo M
Cancers (Basel). 2024; 16(19).
PMID: 39409870
PMC: 11476252.
DOI: 10.3390/cancers16193248.
